ArticleBioMed research international2026
Predictive Analysis on the Mechanism of Dendrobium officinale Polysaccharides in Treating Hepatic Fibrosis via Network Pharmacology and Molecular Docking.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThe possible anti-liver fibrosis (LF) mechanism of Dendrobium officinale polysaccharides (DOP) has been explored, and the potential core targets of monosaccharides therein have been analyzed through network pharmacology and molecular docking techniques.
methodsHigh-performance anion-exchange chromatography (HPAEC) was performed to determine the monosaccharide components of DOP after extraction. In network pharmacology analysis, the TCMSP, SuperPred, SwissTargetPrediction, and PharmMapper databases (for the potential targets of monosaccharides), as well as the GeneCards and OMIM databases (for potential targets of LF), were used to predict the potential targets through which monosaccharides may reverse LF. The STRING database was used to construct a protein-protein interaction (PPI) network, which was visualized using the Cytoscape application. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used for functional annotation and pathway analysis, respectively. In molecular docking, the AutoDock Vina application was used to predict the mechanism of major monosaccharides against LF.
resultsThe extracted DOP contains seven main monosaccharides: glucose (Glu), mannose (Man), xylose (Xyl), galactose (Gal), arabinose (Ara), galacturonic acid (Gal-UA), and rhamnose (Rha). The network pharmacology analysis revealed 15 core targets of DOP monosaccharides against LF. Functional annotation of 427 overlapping targets revealed primary enrichment in cell proliferation, inflammatory response, hypoxia and oxidoreductase activity, extracellular matrix disassembly, abnormal lipid metabolism and peroxidation, ERK1/2 cascade reaction, mitochondrion and ATP binding, and other aspects. At the same time, the signaling pathways involved in these targets are enriched in VEGF, EGFR, HIF-1, FoxO, MAPK, PI3K-Akt-mTOR, AMPK, JAK-STAT, NF-κB, apoptosis, and other pathways. Molecular docking demonstrated that several key-including MAPK3, MMP9, ALB, HSP90αB1, SRC, and NFKB1-exhibited good binding affinities.
conclusionDOP may exert anti-LF effects by affecting EGFR, STAT1, NF-κB, and MAPK pathways to regulate HSC activation, oxidative stress, lipid peroxidation, ferroptosis, and ECM deposition.
Indexed as
Identifiers
42765555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.